STOCK TITAN

[144] Amphastar Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Insider sale notice for AMPH: This Form 144 shows a proposed sale of 500 shares of Amphastar Pharmaceuticals common stock through UBS Financial Services on or about 10/01/2025, with an aggregate market value listed as $13,370.00. The shares were originally acquired as RSUs on 06/07/2022. The filer previously sold three blocks of 500 shares each during July, August and September 2025, generating gross proceeds of $11,733.95, $10,415.75, and $15,491.65 respectively. The filing lists total shares outstanding as 46,495,077, indicating the planned sale is a small fraction of the company’s outstanding shares. The notice includes the signer’s representation that no undisclosed material adverse information about the issuer is known.

Avviso di vendita da insider per AMPH: Questo Form 144 descrive una vendita proposta di 500 azioni ordinarie di Amphastar Pharmaceuticals tramite UBS Financial Services prevista per circa il 01/10/2025, con un valore di mercato aggregato indicato di $13,370.00. Le azioni sono state originariamente acquisite come RSU il 06/07/2022. Il dichiarante ha già venduto in passato tre blocchi di 500 azioni ciascuno nel luglio, agosto e settembre 2025, generando proventi lordi di $11,733.95, $10,415.75 e $15,491.65 rispettivamente. Nella dichiarazione è indicato un totale di azioni in circolazione pari a 46,495,077, a indicare che la vendita prevista rappresenta una piccola frazione delle azioni ordinarie della società. L’avviso include la dichiarazione del firmatario secondo cui non è nota alcuna informazione materiale avversa non divulgata sull’emittente.

Aviso de venta de insider para AMPH: Este Formulario 144 muestra una venta propuesta de 500 acciones ordinarias de Amphastar Pharmaceuticals a través de UBS Financial Services prevista para aproximadamente el 01/10/2025, con un valor de mercado agregado de $13,370.00. Las acciones se adquirieron originalmente como RSU el 06/07/2022. El solicitante ya vendió anteriormente tres bloques de 500 acciones cada uno durante julio, agosto y septiembre de 2025, obteniendo unos ingresos brutos de $11,733.95, $10,415.75 y $15,491.65 respectivamente. El escrito indica un total de 46,495,077 acciones en circulación, lo que señala que la venta prevista representa una pequeña fracción de las acciones en circulación de la empresa. El aviso incluye la declaración de que no se conoce ninguna información adversa material no divulgada sobre el emisor.

AM PH 내부자 매각 공지: 이 Form 144는 UBS Financial Services를 통해 Amphastar Pharmaceuticals의 일반주 500주를 약 2025-10-01에 매각하려는 제안을 보여주며, 총 시가로 $13,370.00으로 기재되어 있습니다. 해당 주식은 원래 2022-06-07에 RSU로 취득되었습니다. 공시는 공시인(신고인)이 이미 2025년 7월, 8월, 9월에 각각 500주씩의 세 묶음을 매각하여 총 매출액으로 $11,733.95, $10,415.75, $15,491.65를 각각 기록했다고 밝히고 있습니다. 보고서는 유통 주식 총수가 46,495,077주로 기재되어 있어 예정된 매도가 회사의 유통 주식 중 작은 부분임을 시사합니다. 또한 이 공시는 발행사에 대해 비공개의 중대한 악재 정보가 알려지지 않았다는 서명을 포함하고 있습니다.

Avis de vente d’initié pour AMPH: Ce Form 144 décrit une vente proposée de 500 actions ordinaires d’Amphastar Pharmaceuticals par UBS Financial Services, prévue vers le 01/10/2025, avec une valeur marchande totale indiquée de $13,370.00. Les actions ont été acquises initialement sous forme de RSU le 06/07/2022. Le déclarant a déjà vendu trois blocs de 500 actions chacun au cours de juillet, août et septembre 2025, générant des produits bruts de $11,733.95, $10,415.75 et $15,491.65 respectivement. Le dossier indique un total d’actions en circulation de 46,495,077, ce qui montre que la vente prévue représente une faible fraction des actions en circulation de la société. L’avis inclut la déclaration du signataire selon laquelle aucune information défavorable matérielle non divulguée sur l’émetteur n’est connue.

Insider-Verkaufshinweis für AMPH: Dieses Formular 144 zeigt einen geplanten Verkauf von 500 Stammaktien von Amphastar Pharmaceuticals über UBS Financial Services am bzw. um den 01.10.2025, mit einem angegebenen Gesamtmarktwert von $13,370.00. Die Aktien wurden ursprünglich als RSU am 06.07.2022 erworben. Der Anzeigende hat bereits in den Monaten Juli, August und September 2025 drei Blöcke à 500 Aktien verkauft, wodurch Bruttoerlöse von $11,733.95, $10,415.75 und $15,491.65 erzielt wurden. Im Bericht wird eine Gesamtzahl ausstehender Aktien von 46,495,077 angegeben, was darauf hindeutet, dass der geplante Verkauf nur einen kleinen Anteil der umlaufenden Aktien des Unternehmens ausmacht. Die Mitteilung enthält die Erklärung des Unterzeichners, dass ihm keine nicht offengelegten wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

إشعار بيع من الداخل لـ AMPH: يعرض هذا النموذج 144 بيعاً مقترحاً لـ 500 سهماً عاديّاً من Amphastar Pharmaceuticals عبر UBS Financial Services في أو نحو 01/10/2025، بقيمة سوقية إجمالية مدونة قدرها $13,370.00. تم الحصول على الأسهم أصلاً كـ RSU في 06/07/2022. كان المُبلغ عنه قد باع سابقاً ثلاث كتل من 500 سهم لكل كتلة خلال أشهر يوليو، أغسطس وسبتمبر 2025، محققاً إيرادات إجمالية قدرها $11,733.95، $10,415.75، و$15,491.65 على التوالي. ويورد الملف إجمالي الأسهم القائمة بـ 46,495,077 سهماً، مما يشير إلى أن البيع المخطط يمثل جزءاً صغيراً من أسهم الشركة المتداولة. كما يتضمن الإشعار representation للموقّع بأن لا معلومات سلبية جوهرية غير مكشوفة عن المصدر معروفة لديه.

AMPH 内部人销售通知: 本 Form 144 显示通过 UBS Financial Services 在大约 2025/10/01 左右拟出售 Amphastar Pharmaceuticals 的 500 股普通股,总市值为 $13,370.00。这些股票最初于 2022/06/07 以 RSU 形式取得。申报者此前在 2025 年 7、8、9 月分别出售了 三批500 股,毛收入分别为 $11,733.95$10,415.75$15,491.65。文件列出流通股总数为 46,495,077 股,表明拟售出只是公司流通股的一小部分。通知还包括签署人表示对发行人没有已知的未披露的重大不利信息。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine insider sale of RSU-derived shares; transaction size is immaterial relative to outstanding shares.

The filer intends to sell 500 shares (~$13.4k) via UBS on 10/01/2025 and has sold three prior 500-share blocks in the past three months. Shares originated from RSUs awarded 06/07/2022. Given the company’s reported outstanding shares of 46,495,077, these transactions represent de minimis dilution or supply impact. The filing complies with Rule 144 disclosure requirements and includes the standard attestation regarding material nonpublic information.

TL;DR: Disclosure appears proper; multiple small disposals suggest personal liquidity rather than signaling company issues.

The Form 144 documents repeated small sales over consecutive months and a planned sale, all sourced from RSUs. From a governance perspective, repeated small insider sales are common for tax or diversification purposes. The seller affirms no undisclosed material adverse information, and the filing names the broker and approximate sale date, satisfying procedural requirements. There is no indication of unusual timing or materiality in this filing.

Avviso di vendita da insider per AMPH: Questo Form 144 descrive una vendita proposta di 500 azioni ordinarie di Amphastar Pharmaceuticals tramite UBS Financial Services prevista per circa il 01/10/2025, con un valore di mercato aggregato indicato di $13,370.00. Le azioni sono state originariamente acquisite come RSU il 06/07/2022. Il dichiarante ha già venduto in passato tre blocchi di 500 azioni ciascuno nel luglio, agosto e settembre 2025, generando proventi lordi di $11,733.95, $10,415.75 e $15,491.65 rispettivamente. Nella dichiarazione è indicato un totale di azioni in circolazione pari a 46,495,077, a indicare che la vendita prevista rappresenta una piccola frazione delle azioni ordinarie della società. L’avviso include la dichiarazione del firmatario secondo cui non è nota alcuna informazione materiale avversa non divulgata sull’emittente.

Aviso de venta de insider para AMPH: Este Formulario 144 muestra una venta propuesta de 500 acciones ordinarias de Amphastar Pharmaceuticals a través de UBS Financial Services prevista para aproximadamente el 01/10/2025, con un valor de mercado agregado de $13,370.00. Las acciones se adquirieron originalmente como RSU el 06/07/2022. El solicitante ya vendió anteriormente tres bloques de 500 acciones cada uno durante julio, agosto y septiembre de 2025, obteniendo unos ingresos brutos de $11,733.95, $10,415.75 y $15,491.65 respectivamente. El escrito indica un total de 46,495,077 acciones en circulación, lo que señala que la venta prevista representa una pequeña fracción de las acciones en circulación de la empresa. El aviso incluye la declaración de que no se conoce ninguna información adversa material no divulgada sobre el emisor.

AM PH 내부자 매각 공지: 이 Form 144는 UBS Financial Services를 통해 Amphastar Pharmaceuticals의 일반주 500주를 약 2025-10-01에 매각하려는 제안을 보여주며, 총 시가로 $13,370.00으로 기재되어 있습니다. 해당 주식은 원래 2022-06-07에 RSU로 취득되었습니다. 공시는 공시인(신고인)이 이미 2025년 7월, 8월, 9월에 각각 500주씩의 세 묶음을 매각하여 총 매출액으로 $11,733.95, $10,415.75, $15,491.65를 각각 기록했다고 밝히고 있습니다. 보고서는 유통 주식 총수가 46,495,077주로 기재되어 있어 예정된 매도가 회사의 유통 주식 중 작은 부분임을 시사합니다. 또한 이 공시는 발행사에 대해 비공개의 중대한 악재 정보가 알려지지 않았다는 서명을 포함하고 있습니다.

Avis de vente d’initié pour AMPH: Ce Form 144 décrit une vente proposée de 500 actions ordinaires d’Amphastar Pharmaceuticals par UBS Financial Services, prévue vers le 01/10/2025, avec une valeur marchande totale indiquée de $13,370.00. Les actions ont été acquises initialement sous forme de RSU le 06/07/2022. Le déclarant a déjà vendu trois blocs de 500 actions chacun au cours de juillet, août et septembre 2025, générant des produits bruts de $11,733.95, $10,415.75 et $15,491.65 respectivement. Le dossier indique un total d’actions en circulation de 46,495,077, ce qui montre que la vente prévue représente une faible fraction des actions en circulation de la société. L’avis inclut la déclaration du signataire selon laquelle aucune information défavorable matérielle non divulguée sur l’émetteur n’est connue.

Insider-Verkaufshinweis für AMPH: Dieses Formular 144 zeigt einen geplanten Verkauf von 500 Stammaktien von Amphastar Pharmaceuticals über UBS Financial Services am bzw. um den 01.10.2025, mit einem angegebenen Gesamtmarktwert von $13,370.00. Die Aktien wurden ursprünglich als RSU am 06.07.2022 erworben. Der Anzeigende hat bereits in den Monaten Juli, August und September 2025 drei Blöcke à 500 Aktien verkauft, wodurch Bruttoerlöse von $11,733.95, $10,415.75 und $15,491.65 erzielt wurden. Im Bericht wird eine Gesamtzahl ausstehender Aktien von 46,495,077 angegeben, was darauf hindeutet, dass der geplante Verkauf nur einen kleinen Anteil der umlaufenden Aktien des Unternehmens ausmacht. Die Mitteilung enthält die Erklärung des Unterzeichners, dass ihm keine nicht offengelegten wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Amphastar Pharma

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Latest SEC Filings

AMPH Stock Data

1.24B
35.33M
24.02%
71.85%
8.94%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA